Ho Pei, Lu Mingxi, Meng Lingyan, Hongsakul Keerati
Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Department of Cardiac, Thoracic and Vascular Surgery, National University Health System, Singapore.
J Vasc Access. 2025 Jul;26(4):1294-1302. doi: 10.1177/11297298241273610. Epub 2024 Aug 24.
Resistant chronic total occlusion (CTO) lesions present an ongoing challenge for conventional endovascular interventions to restore functional hemodialysis (HD) access. This study endeavors to present a novel endovascular approach utilizing ultrasound (USG)-guided percutaneous sharp recanalization to cross the resistant occlusions and evaluates its effectiveness.
This is a multi-center retrospective review of consecutive patients received USG guided sharp recanalization for the treatment of resistant CTO lesions of their HD access between 1st January 2019 and 31st July 2023. Data encompassing patient demographics, access and lesion characteristics, procedural specifics, associated complications, immediate clinical outcomes, and outcomes during follow-up were collected. The procedural technical and clinical success, Kaplan-Meier estimated target lesion (TLPP), access circuit primary patency (ACPP), and index access secondary patency (SP) were reported.
During the study period, 22 patients underwent USG-guided sharp recanalization procedures in the three participating centers with median follow-up of 14.5 months. Both the technical and clinical success were 100%. Only two patients experienced minor complications of localized hematoma over the access, with no instances of major complication. Kaplan-Meier estimated TLPP and ACPP at 3-, 6-, and 12 months were 90.9%, 68.2%, 56.8%, and 90.9%, 63.6%, 52.1% respectively. The SP rates were 100%, 95.5%, and 84.1% at 3-, 6-, and 12 months respectively.
USG guided percutaneous sharp recanalization is an effective and safe endovascular approach to treat resistant CTO lesions of dysfunctional HD access.
对于传统血管内介入治疗以恢复功能性血液透析(HD)通路而言,难治性慢性完全闭塞(CTO)病变一直是一项挑战。本研究旨在提出一种利用超声(USG)引导下经皮锐性再通术穿过难治性闭塞病变的新型血管内方法,并评估其有效性。
这是一项多中心回顾性研究,对2019年1月1日至2023年7月31日期间接受USG引导下锐性再通术治疗HD通路难治性CTO病变的连续患者进行分析。收集了包括患者人口统计学、通路和病变特征、手术细节、相关并发症、即时临床结果以及随访期间结果等数据。报告了手术技术和临床成功率、Kaplan-Meier估计的靶病变通畅率(TLPP)、通路回路初级通畅率(ACPP)以及索引通路次级通畅率(SP)。
在研究期间,三个参与中心的22例患者接受了USG引导下的锐性再通术,中位随访时间为14.5个月。技术成功率和临床成功率均为100%。仅2例患者在通路部位出现局部血肿的轻微并发症,无严重并发症发生。Kaplan-Meier估计的3个月、6个月和12个月时的TLPP分别为90.9%、68.2%、56.8%,ACPP分别为90.9%、63.6%、52.1%。3个月、6个月和12个月时的SP率分别为100%、95.5%和84.1%。
USG引导下经皮锐性再通术是治疗功能失调的HD通路难治性CTO病变的一种有效且安全的血管内方法。